{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:51:29Z","timestamp":1740178289267,"version":"3.37.3"},"reference-count":18,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,12]]},"DOI":"10.1182\/bloodadvances.2022006964","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T15:31:13Z","timestamp":1657035073000},"page":"3875-3878","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9009","authenticated-orcid":false,"given":"Alberto","family":"Fresa","sequence":"first","affiliation":[{"name":"1Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy;"},{"name":"2Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7868-7469","authenticated-orcid":false,"given":"Francesco","family":"Autore","sequence":"additional","affiliation":[{"name":"2Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[{"name":"3Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Foundation, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-9525","authenticated-orcid":false,"given":"Gioacchino","family":"Catania","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":false,"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[{"name":"5Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Tomasso","sequence":"additional","affiliation":[{"name":"1Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1161-9995","authenticated-orcid":false,"given":"Marina","family":"Moretti","sequence":"additional","affiliation":[{"name":"6Reparto di Oncoematologia Azienda Ospedaliera Santa Maria di Terni, Terni, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2592-8724","authenticated-orcid":false,"given":"Candida","family":"Vitale","sequence":"additional","affiliation":[{"name":"7University Division of Hematology, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy;"},{"name":"8Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Morelli","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Universit\u00e0 degli Studi di Firenze, Florence, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-9862","authenticated-orcid":false,"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[{"name":"11Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-6878","authenticated-orcid":false,"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"12Hematology Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0149-0764","authenticated-orcid":false,"given":"Giuseppe","family":"Sapienza","sequence":"additional","affiliation":[{"name":"13Division of Oncohematology, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-1839","authenticated-orcid":false,"given":"Annarosa","family":"Cuccaro","sequence":"additional","affiliation":[{"name":"14Hematology Unit, Center for Translational Medicine, Azienda USL Toscana NordOvest, Livorno, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Murru","sequence":"additional","affiliation":[{"name":"15Hematology and Stem Cell Transplantation Unit, Ospedale A. Businco, Cagliari, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sanna","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"13Division of Oncohematology, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Angeletti","sequence":"additional","affiliation":[{"name":"6Reparto di Oncoematologia Azienda Ospedaliera Santa Maria di Terni, Terni, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[{"name":"7University Division of Hematology, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy;"},{"name":"8Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6149","authenticated-orcid":false,"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[{"name":"5Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Pietrasanta","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7290-260X","authenticated-orcid":false,"given":"Idanna","family":"Innocenti","sequence":"additional","affiliation":[{"name":"2Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-1396","authenticated-orcid":false,"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[{"name":"1Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy;"},{"name":"2Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"issue":"12","key":"2022070515310097900_B1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med."},{"issue":"7-8","key":"2022070515310097900_B2","first-page":"421","article-title":"Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities \u2013 Polish Adult Leukemia Group (PALG) real-life analysis","volume":"128","author":"D\u0142ugosz-Danecka","year":"2018","journal-title":"Pol Arch Intern Med."},{"issue":"6","key":"2022070515310097900_B3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25766","article-title":"Frontline treatment with the combination obinutuzumab \u00b1 chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group","volume":"95","author":"Herishanu","year":"2020","journal-title":"Am J Hematol."},{"issue":"4","key":"2022070515310097900_B4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/hon.2744","article-title":"Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: the GO-CLLEAR Study by the Czech CLL Study Group","volume":"38","author":"Panovsk\u00e1","year":"2020","journal-title":"Hematol Oncol."},{"issue":"1","key":"2022070515310097900_B5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2012.070755","article-title":"Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia","volume":"98","author":"Bouvet","year":"2013","journal-title":"Haematologica."},{"key":"2022070515310097900_B6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2016.03.069","article-title":"Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials","volume":"60","author":"Gentile","year":"2016","journal-title":"Eur J Cancer."},{"issue":"3","key":"2022070515310097900_B7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/hon.2837","article-title":"Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia","volume":"39","author":"Fresa","year":"2021","journal-title":"Hematol Oncol."},{"issue":"21","key":"2022070515310097900_B8","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V124.21.1312.1312","article-title":"Impact of comorbidities on treatment outcomes in chronic lymphocytic leukemia: a retrospective analysis","volume":"124","author":"Manda","year":"2014","journal-title":"Blood."},{"issue":"11","key":"2022070515310097900_B9","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00277-018-3409-3","article-title":"Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia","volume":"97","author":"Strugov","year":"2018","journal-title":"Ann Hematol."},{"issue":"3","key":"2022070515310097900_B10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bjh.17032","article-title":"Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients","volume":"191","author":"Mattsson","year":"2020","journal-title":"Br J Haematol."},{"issue":"9","key":"2022070515310097900_B11","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.3324\/haematol.2016.156901","article-title":"Chlorambucil plus rituximab as front-line therapy for elderly and\/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification","volume":"102","author":"Laurenti","year":"2017","journal-title":"Haematologica."},{"key":"2022070515310097900_B12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3389\/fonc.2020.00848","article-title":"Front-line therapy for elderly chronic lymphocytic leukemia patients: bendamustine plus rituximab or chlorambucil plus rituximab? Real-life retrospective multicenter study in the Lazio region","volume":"10","author":"Autore","year":"2020","journal-title":"Front Oncol."},{"issue":"15","key":"2022070515310097900_B13","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer."},{"issue":"22","key":"2022070515310097900_B14","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1002\/cam4.3470","article-title":"Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study","volume":"9","author":"Cuneo","year":"2020","journal-title":"Cancer Med."},{"issue":"24","key":"2022070515310097900_B15","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/bloodadvances.2021004824","article-title":"Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?","volume":"5","author":"Tedeschi","year":"2021","journal-title":"Blood Adv."},{"issue":"21","key":"2022070515310097900_B16","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.3390\/jcm10215104","article-title":"Treatment options for elderly\/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: a comprehensive review","volume":"10","author":"Fresa","year":"2021","journal-title":"J Clin Med."},{"issue":"23","key":"2022070515310097900_B17","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med."},{"issue":"9","key":"2022070515310097900_B18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3875\/1905022\/advancesadv2022006964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3875\/1905022\/advancesadv2022006964.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T15:31:30Z","timestamp":1657035090000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/13\/3875\/485144\/Relative-dose-intensity-of-obinutuzumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":18,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,7,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022006964","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2022,7,5]]}}}